APRINOIA Therapeutics Inc. has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-08-28. Amendments on record here: 2. It asked for the registration statement to be withdrawn on 2024-10-28. Each fact below is quoted from the filing named with it.
What the filings say
Listing
We have applied for the listing of the ordinary shares on the Nasdaq Global Market (“Nasdaq”), under the symbol “APRI.” There is no assurance that such application will be approved, and if our application is not approved, this offering will not be completed.From the F-1/A filed 2024-09-11
Shares offered
This is an initial public offering of the ordinary shares of APRINOIA Therapeutics Inc. We are offering 500,000 ordinary shares, par value $0.40 per share.From the F-1/A filed 2024-09-11
Price range
We expect that the initial public offering price will be between $10.00 and $12.00 per ordinary share.From the F-1/A filed 2024-09-11
Use of proceeds
We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to advance the clinical development of APN-1607 and APNmAb005, research and development of our degrader therapeutic candidates, other research and development activities as well as for working capital and other general corporate purposes.From the F-1/A filed 2024-09-11
Net loss or income
For the years ended December 31, 2023 and 2022, our net losses were $28.6 million and $28.2 million, respectively.From the F-1/A filed 2024-09-11
Withdrawal
Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “ Securities Act ”), APRINOIA Therapeutics Inc. (the “ Company ”) hereby requests that, effective as of the date first set forth above, the Securities and Exchange Commission (the “ Commission ”) consent to the withdrawal of the Company’s registration statement on Form F-1 (File No. 333-276696) (together with the exhibits and supplements thereto, the “ Registration Statement ”).From the RW filed 2024-10-28
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-08-28 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-09-11 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-10-28 | Request to withdraw a registration (Form F-1) | RW |
Tools for this story
Each opens in a new tab, filled in for APRINOIA Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.